The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Can BiTEs and CAR T-cells be used to treat MCL?
Stephen Ansell, MD, PhD, from the Mayo Clinic, Rochester, MN, USA, provides an overview concerning the immunotherapeutic opportunities in the treatment of mantle cell lymphoma (MCL). He explains that although there is little known regarding immune responses in lymphoma, there have been promising results from studies focused on treating MCL with bispecific T-cell engagers (BiTEs) and CAR T-cells. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
